Results released Monday from a Phase 2 study of a chronic cough treatment being developed by Bellus Health exceeded the expectations of financial analysts and boost the company’s chances of eventual approval after an earlier trial of the drug had failed.
Bellus said in a press release it expects to meet with the Food and Drug Administration in the second quarter of 2022 and to begin a Phase 3 study of the treatment in the second half of 2022. Roberto Bellini, Bellus’ CEO, said the company is “extremely pleased” with the “compelling” results.
Results with the lowest 12-milligram dose of the treatment, BLU-5937, were not statistically significant. But results for the 50-milligram and 200-milligram doses were significant, reducing the frequency of coughs by 34.4% and 34.2%, respectively.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
